TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6344196

Group type: EXPERIMENTAL
Intervention: Griseofulvin treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study: 31311097

Group type: EXPERIMENTAL
Intervention: Inclined bench press at 12% of 1 repetition maximum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inclined bench press at 24% of 1 repetition maximum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Leg extension exercise at 12% of 1 repetition maximum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Leg extension exercise at 24% of 1 repetition maximum
Number of subjects: 12
Study: 30154493

Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 376

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 376
Study: 26411813

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) to the left lower extremity using a blood pressure cuff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (cuff applied but not inflated or deflated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24462484

Group type: EXPERIMENTAL
Intervention: 0.50g/kg alcohol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3.57mL/kg ED
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AmED
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ED
Number of subjects: 28
Study: 22186668

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbidopa‐levodopa administration
Number of subjects: 0
Study: 20629547

Group type: EXPERIMENTAL
Intervention: Puros Dermis (PDM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alloderm (ADM)
Number of subjects: 14
Study: 17574929

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day, n=25)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (n=26)
Number of subjects: 51
Study: 16359281

Group type: EXPERIMENTAL
Intervention: Structured 8-week educational telephone intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 168
Study: 12412495

Group type: EXPERIMENTAL
Intervention: Case version under time pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case version under no time pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pro-plaintiff beliefs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pro-defendant beliefs
Number of subjects: 0
Study: 9674467

Group type: EXPERIMENTAL
Intervention: Adenosine (maximum dose, 0.05 mg/kg/min)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Substance P (maximum dose, 100 pmol/min)
Number of subjects: 17
Study: 8568008

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily for 13 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2152777

Group type: EXPERIMENTAL
Intervention: Dietary fiber (20 mg corn fiber in 4 cookies daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dietary fiber
Number of subjects: 14
Study: 25288

Group type: EXPERIMENTAL
Intervention: Triazolam 0.6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurazepam 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 31490407

Group type: EXPERIMENTAL
Intervention: Simulation based training
Number of subjects: 51

Group type: COMPARATOR
Intervention: E-learning
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hands-on training
Number of subjects: 51
Study: 29107197

Group type: EXPERIMENTAL
Intervention: PEACH™ intervention
Number of subjects: 37
Study: 25440437

Group type: EXPERIMENTAL
Intervention: Lignin peroxidase
Number of subjects: 60
Study: 23800112

Group type: EXPERIMENTAL
Intervention: Global Rating Scale (GRS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Checklists
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two raters
Number of subjects: 60
Study: 21925909

Group type: EXPERIMENTAL
Intervention: PSA nerve block using lignocaine with vasoconstrictor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Maxillary infiltration for anesthesia
Number of subjects: 100
Study: 19202451

Group type: EXPERIMENTAL
Intervention: Preemptive therapy or antiviral prophylaxis (valacyclovir or ganciclovir) for 3 months in 60 patients
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CMV viremia with viral load of more than or equal to 2000 copies/mL
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Biopsy-proven acute rejection
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sirolimus-based immunosuppression
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Delayed-graft function
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Donor age (per 10-year increase)
Number of subjects: 118
Study: 16545748

Group type: EXPERIMENTAL
Intervention: Immediate treatment with antiepileptic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed treatment with antiepileptic drugs
Number of subjects: 0
Study: 14580077

Group type: EXPERIMENTAL
Intervention: BZD withdrawal (group A)
Number of subjects: 192

Group type: COMPARATOR
Intervention: BZD continuation (group C)
Number of subjects: 192

Group type: COMPARATOR
Intervention: BZD continuation (group B)
Number of subjects: 192
Study: 10932338

Group type: EXPERIMENTAL
Intervention: Ava Neb 1780 (output 205 +/- 13 mg/min)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hudson UP Draft II 1730 (output 356 +/- 31 mg/min)
Number of subjects: 27
Study: 8986486

Group type: EXPERIMENTAL
Intervention: Norepinephrine treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Severe sepsis (no norepinephrine)
Number of subjects: 28
Study: 1594414

Group type: EXPERIMENTAL
Intervention: Positive reinforcement group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Group given statements of personal importance
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 6085804

Group type: EXPERIMENTAL
Intervention: Polymyxin B/gramicidin ear drop combination at bedtime on the day they swam
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Strict rules to prevent water entering the ear (bathing caps, earplugs)
Number of subjects: 1000
Study: 31412290

Group type: EXPERIMENTAL
Intervention: Trehalose
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carboxymethylcellulose (CMC)
Number of subjects: 9
Study: 30111683

Group type: EXPERIMENTAL
Intervention: Paprika xanthophyll capsules (9.0 mg of paprika xanthophylls)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 100
Study: 27417947

Group type: EXPERIMENTAL
Intervention: Levobupivacaine with epinephrine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Levobupivacaine without epinephrine
Number of subjects: 11
Study: 24507417

Group type: EXPERIMENTAL
Intervention: INSPIRED (Individual Support & Resources for Diabetes) Manual with Health Coach support over seven weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Fact sheets containing key information about diabetes self-management
Number of subjects: 180
Study: 23135080

Group type: COMPARATOR
Intervention: Superpulse-mode fractional CO2 laser (SPCO2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ultrapulse-mode fractional CO2 laser (UPCO2)
Number of subjects: 18
Study: 20417293

Group type: EXPERIMENTAL
Intervention: NSAIDs with flare design
Number of subjects: 20915

Group type: COMPARATOR
Intervention: NSAIDs without flare design
Number of subjects: 20915
Study: 17951267

Group type: COMPARATOR
Intervention: Standard Approach (SA)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Tailored Approach (TA)
Number of subjects: 198
Study: 16304442

Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1100 microg F/g) after lunch
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice (550 microg F/g) on fasting
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (0 microg F/g)
Number of subjects: 11
Study: 12546171

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (90 mL mixed with 300 mL clear liquid and 4-5 glasses of water)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyethylene glycol solution (2 liters)
Number of subjects: 100
Study: 11202131

Group type: EXPERIMENTAL
Intervention: Mianserin 60 mg/day plus fluoxetine 20 mg/day
Number of subjects: 104

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Mianserin 60 mg/day
Number of subjects: 104
Study: 9458419

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 8195448

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine/0.022% sodium fluoride rinse
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine fluoride rinse
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 18
Study: 2466056

Group type: EXPERIMENTAL
Intervention: 200 mg of pirmenol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 250 mg of pirmenol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 300 mg of pirmenol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29790382

Group type: EXPERIMENTAL
Intervention: Low ventilation (LV, respiratory rate ≤8/minute and tidal volume <500 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard ventilation (SV)
Number of subjects: 60
Study: 26792238

Group type: EXPERIMENTAL
Intervention: Prearrival instructions including the specific location of AEDs
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no location information provided)
Number of subjects: 39
Study: 25709404

Group type: EXPERIMENTAL
Intervention: Viron (three tablets twice daily)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Viron (two tablets twice daily)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Viron (one tablet twice daily)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Viron (highest dose)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study: 23631785

Group type: EXPERIMENTAL
Intervention: Perceived peer social support for physical activity
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Neighborhood walkability
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 434
Study: 20157845

Group type: EXPERIMENTAL
Intervention: Promised incentive of one lottery ticket to be received upon reply
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week
Number of subjects: 450

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Overall response across all groups
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Comparison of response curves between no incentive and incentive groups
Number of subjects: 450
Study: 18254429

Group type: EXPERIMENTAL
Intervention: Model program
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 65
Study: 17444155

Group type: EXPERIMENTAL
Intervention: Terasosine (setegis) 1 mg twice a day for 2 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12894960

Group type: EXPERIMENTAL
Intervention: Community health worker intervention (nurse-supervised, trained in blood pressure management)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community health worker intervention (2 different levels of intensity)
Number of subjects: 0
Study: 10966997

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg taken once every 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Number of subjects: 100
Study: 8864322

Group type: EXPERIMENTAL
Intervention: Thyrotrophin releasing hormone (TRH) 50 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyrotrophin releasing hormone (TRH) 200 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyrotrophin releasing hormone (TRH) 500 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ganglion blocking drug pentolinium (5 mg) with TRH 500 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-adrenoceptor blockade with thymoxamine (0.3 mg kg-1 bolus + 0.3 mg kg-1 h-1 infusion) with TRH 500 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol (10 mg i.v. over 10 min) with TRH 500 micrograms
Number of subjects: 0
Study: 1728909

Group type: EXPERIMENTAL
Intervention: Automated blood pressure monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Casual office blood pressure measurement
Number of subjects: 0
Study: 29786678

Group type: EXPERIMENTAL
Intervention: Early physical rehabilitation for in-patients (n=25)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Personality-oriented program for physical rehabilitation (first group n=45)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Personality-oriented program for physical rehabilitation (second group n=40)
Number of subjects: 135
Study: 27478925

Group type: EXPERIMENTAL
Intervention: Late mealtimes (4.5, 8.5, 14.5 and 16 hours after awakening)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Normal mealtimes (1, 5, 11 and 12.5 hours after awakening)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Late sleep/normal meal
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Normal sleep/late meal
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Late sleep/late meal
Number of subjects: 4

Group type: COMPARATOR
Intervention: Normal sleep/normal meal
Number of subjects: 4
Study: 23574999

Group type: EXPERIMENTAL
Intervention: Carperitide infusion
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 22627104

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus oxaliplatin
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Fluorouracil alone
Number of subjects: 1236
Study: 20825986

Group type: EXPERIMENTAL
Intervention: Celiprolol (up to 400 mg per day, administered twice daily, titrated by 100 mg every 6 months)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 53
Study: 18522634

Group type: EXPERIMENTAL
Intervention: Colposcopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 0
Study: 16855464

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg up to 100 mg per usage)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 14587682

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11061616

Group type: EXPERIMENTAL
Intervention: GM-CSF (450 microg/m2 days 4-5 and 15-16)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GM-CSF (450 microg/m2 days 4-5 and 15-16) plus (225 microg/m2 days 6-10 and 17-21)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GM-CSF (450 microg/m2 days 4-10 and 15-21)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Increasing GM-CSF doses
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 19
Study: 9311404

Group type: EXPERIMENTAL
Intervention: Lidocaine (2‐min bolus, 100 mg; 15 min infusion, 40 micrograms.kg‐1.min‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8320947

Group type: EXPERIMENTAL
Intervention: Acetate Hemodialysis (AHD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bicarbonate Hemodialysis (BHD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetate-free Biofiltration (AFB)
Number of subjects: 12
Study: 2947606

Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides (600 mg, four times before smoking)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 29533715

Group type: EXPERIMENTAL
Intervention: Internal focus group (INTERNAL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: External focus group (EXTERNAL)
Number of subjects: 30
Study: 27507627

Group type: EXPERIMENTAL
Intervention: Buccal infiltration of 0.7 mL 8.4% sodium bicarbonate with 0.3 mL 2% lidocaine containing 1:80,000 epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received 0.7 mL sterile distilled water with 0.3 mL 2% lidocaine containing 1:80,000 epinephrine
Number of subjects: 100
Study: 24907722

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (86 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Continuous erythropoietin receptor activator (34 patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 120
Study: 22540433

Group type: EXPERIMENTAL
Intervention: Tramadol (600 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Methadone (60 mg/day)
Number of subjects: 70
Study: 20299774

Group type: EXPERIMENTAL
Intervention: Lidocaine suppository (60 mg or 120 mg) + PNB
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine gel (10 ml of 2% lidocaine) + PNB
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo suppository + PNB
Number of subjects: 100

Group type: COMPARATOR
Intervention: PNB alone
Number of subjects: 100
Study: 19317172

Group type: EXPERIMENTAL
Intervention: Shufeng Liangxue Decoction (SLD)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Symptomatic Western medical therapy (Control)
Number of subjects: 116
Study: 15961159

Group type: EXPERIMENTAL
Intervention: Conventional scleral buckling
Number of subjects: 225

Group type: COMPARATOR
Intervention: Primary vitrectomy
Number of subjects: 225
Study: 12912714

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (875 mg amoxicillin and 125 mg clavulanic acid, twice daily for 6 days)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 10608400

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA 0.05 mmol/kg (group A)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA 0.1 mmol/kg (group B)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA 0.2 mmol/kg (group C)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Gd-BOPTA (all groups)
Number of subjects: 201
Study: 8618198

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (75 mg/kg administered orally)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Midazolam (0.2 mg/kg administered intravenously)
Number of subjects: 7
Study: 2006346

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural analgesia (TEA) with bupivacaine 0.75% pre- and intraoperatively, followed by bupivacaine 0.25% continuously for 3 days.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural analgesia (TEA) with bupivacaine.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Balanced anesthesia (isoflurane plus fentanyl) with systemic analgesia on request (piritramide i.m., tramadol, or a simple analgesic).
Number of subjects: 116
Study: 6756262

Group type: EXPERIMENTAL
Intervention: High-dosage Vitamin E treatment (target serum E levels, 5-6 mg/dl)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-Vitamin E treatment (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment from birth (pilot studies, target serum E levels, 1.5 and 3.0 mg/dl)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prestudy infants (1968-72) fed early iron supplements and given formulas with low E:PUFA ratios
Number of subjects: 24
Study: 31837240

Group type: EXPERIMENTAL
Intervention: Blonanserin
Number of subjects: 264

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 264
Study: 31132015

Group type: EXPERIMENTAL
Intervention: Positively-framed information
Number of subjects: 134

Group type: COMPARATOR
Intervention: Negatively-framed information
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: All participants (following Ice Bucket Challenge)
Number of subjects: 134
Study: 28222871

Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-adhesive resin cement
Number of subjects: 20
Study: 26232122

Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (KT) applied over the rectus femoris muscle
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo Taping (PT) using adhesive nonelastic tape over the rectus femoris muscle
Number of subjects: 22
Study: 23797459

Group type: EXPERIMENTAL
Intervention: Smooth Pursuit Therapy (SPT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Visual Scanning Therapy (VST)
Number of subjects: 50
Study: 20979013

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA) 1 g/10 mL in 20 mL of 5% glucose
Number of subjects: 660

Group type: COMPARATOR
Intervention: Placebo (30 mL 5% glucose)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA)
Number of subjects: 660
Study: 19302083

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg daily for 3 days prior to quit date, then 50 mg daily for 8 weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: COMPARATOR
Intervention: Naltrexone and Placebo
Number of subjects: 78
Study: 17587398

Group type: EXPERIMENTAL
Intervention: Repaglinide 1.0 mg three times daily (t.i.d.)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Nateglinide 90 mg three times daily (t.i.d.)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 230
Study: 12698086

Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppression (no steroids)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Steroid treatment (long-term and short-term)
Number of subjects: 27